Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

Summary

In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.

Timeline

Start

2020-02-08

Primary completion

2020-03-12

Completion

2020-12-30

Outcome

Met primary endpoint

paper The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group PMID 35830201 ↗

paper difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P   =  0.008 PMID 35830201 ↗

Publications

• Zhao J, Zhang J, Jin Y, Tang Z, Hu K, Sun H, Shi M, Yang Q, Gu P, Guo H, Li Q, Zhang H, Li C, Yang M, Xiong N, Dong X, Xu J, Lin F, Wang T, Yang C, Huang B, Zhang J, Chen S, He Q, Zhou M, Qu J. A trial of arbidol hydrochloride in adults with COVID-19. Chin Med J (Engl). 2022 Jul 5;135(13):1531-1538. doi: 10.1097/CM9.0000000000002104.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Umifenovir	Small molecule	200 mg	Oral

Indications